Search the Newsreel

IMTX|Immatics NV|Price:8.660|Chg%:-0.540

This article provides an in-depth analysis of Immatics NV (IMTX) stock, including real-time quotes, key financial figures, and market trends. It highlights the company's strong fundamentals, high growth potential, and "Strong Buy" analyst ratings with significant upside potential. The report also details Immatics NV's …

Immunovant (Nasdaq:IMVT) - Stock Analysis

This Simply Wall St analysis of Immunovant (IMVT) provides an overview of the company's financial health, future growth prospects, past performance, and insider transactions. It highlights the company's focus on developing targeted therapies for autoimmune diseases, particularly IMVT-1402, and discusses recent news, analyst ratings, …

Immunome Stock Price Forecast. Should You Buy IMNM?

BMNR Stock Grinds Higher As Traders Track Key Levels

BitMine Immersion Technologies Inc. (BMNR) has shown strong upward momentum despite negative sentiment from recent headlines, with shares climbing from the mid-$14s to high-$17s in July. The company exhibits strong liquidity with high cash and minimal debt but struggles with deeply negative profitability ratios. …

Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors

Zimmer Biomet Holdings Inc. (ZBH) stock fell 1.08% on Friday, closing at $93.93, despite a generally positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marked the second consecutive day of losses …

AC Immune SA Revenue Breakdown – HAM:IMR

AC Immune SA generated €3.84 million in revenue last year, primarily from its Therapeutic and Diagnostic Products segment, which contributed €3.66 million. This is a significant decrease from the previous year's €29.95 million. The majority of this revenue, €3.66 million, originated from Switzerland.

Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLAW

This article from TradingView is a placeholder or an incomplete data point regarding the number of shareholders for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It currently shows no specific shareholder data, indicating that the information is either unavailable or has not yet been populated for …

BMNR Stock Grinds Higher As Traders Watch Tight Range

Shares of BitMine Immersion Technologies Inc. (BMNR) have seen a significant climb in July, moving from the mid-$14s to the high-$17s, despite reporting substantial net losses. The company exhibits a "high-growth, high-burn" profile, backed by a strong balance sheet with considerable cash and minimal …

Cathie Wood trims Ethereum exposure on 11th anniversary

ARK Invest CEO Cathie Wood is one of the first investors to gain exposure to cryptocurrencies. She once revealed that ARK was the first public asset manager to gain Bitcoin (BTC) exposure in 2015 when the cryptocurrency wasn't worth even $500. Related: Cathie Wood …

BitMine Immersion Technologies (NYSE:BMNR) Trading Down 8.1% - Here's Why

BitMine Immersion Technologies (NYSE:BMNR) saw its shares drop 8.1% to $16.61, with trading volume significantly below average, pushing the stock below its 200-day moving average. Analyst opinions are mixed, with some firms reiterating sell ratings or cutting price targets, while the consensus remains a …

Why Is BitMine Immersion Technologies Stock Falling on Friday?

BitMine Immersion Technologies (BMNR) stock is down on Friday due to a broader decline in crypto-linked equities, spurred by drops in Bitcoin and Ethereum, and disappointing Q2 earnings from Coinbase. Regulatory uncertainty surrounding the CLARITY Act, with analysts giving it a low chance of …

Scinai Immunotherapeutics Ltd (SCNI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Scinai Immunotherapeutics Ltd (SCNI), noting its current score of 1.75 and ranking within the Biotechnology & Medical Research industry. It highlights the company's beta value of 2.09, indicating high volatility relative to the S&P 500 index. The …

Mizuho Lifts Price Target on Immunocore Holdings to $35 From $34, Keeps Neutral Rating

Mizuho has increased its price target for Immunocore Holdings (IMCR) to $35 from $34, while maintaining a Neutral rating on the stock. This adjustment reflects a modest positive outlook from the firm regarding the biopharmaceutical company's valuation.

IMMX INVESTIGATION: Immix Biopharma Investors Who Lost Money After Reports About Its Former CMO Should Contact Block & Leviton

Block & Leviton is investigating Immix Biopharma (NASDAQ:IMMX) for potential securities law violations after reports surfaced that a former executive, identified as "Richard Graydon," was allegedly a fugitive operating under a false identity. Immix Biopharma shares fell approximately 10.83% on the day this report …

Immersion Corp (IMMR) Financial Health: Profitability & Balance Sheet Analysis

Immersion Corp (IMMR) currently holds a financial score of 8.93, ranking 33 out of 486 in the Software & IT Services industry, indicating stable financial status and high operating efficiency. Despite this, the company's latest quarterly revenue decreased by 5.22% year-over-year, and its net …

AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis

AC Immune SA (ACIU) has a weak financial status and low operating efficiency, ranking 351 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.50. Despite this, its latest quarterly revenue increased by 19.51% year-over-year to $1.43 million, …

Altimmune Inc Today's Market Trends | ALT Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides a detailed analysis of Altimmune Inc (ALT) stock, highlighting its market trends, real-time quotes, and trading strategies. It covers key financial figures, institutional ownership, analyst ratings, and the company's biopharmaceutical pipeline, including pemvidutide for obesity and MASH. Despite recent stock performance, …

Immersion (IMMR) to Announce Quarterly Earnings on Friday

ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis

ImmuCell Corp (ICCC) has a stable financial status with a current score of 8.98, ranking it 17th out of 155 in the Pharmaceuticals industry. The company demonstrated high operating efficiency with its latest quarterly revenue increasing by 28.39% year-over-year to $10.36M, and net profit …

Possible Bearish Signals With Zimmer Biomet Holdings Insiders Disposing Stock

This article analyzes recent insider selling at Zimmer Biomet Holdings, where insiders disposed of shares worth US$4.4 million over the last year. Despite the selling, the company's stock is up 12% in the past year, indicating that insider selling alone isn't a strong indicator …

Shimmick Corp (SHIM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Shimmick Corp (SHIM), indicating its current valuation score is 7.93, ranking it 22nd out of 42 in the Construction & Engineering industry. It notes a P/E ratio of -6.55, which is significantly below its recent high and …

Immatics NV (IMTX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Immatics NV (IMTX), noting its current valuation score of 6.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -12.17, which is significantly below its recent high and above its recent …

IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease

ImmunityBio (IBRX) stock jumped nearly 8% after the UAE granted its cancer immunotherapy, Anktiva, its broadest approval yet for bladder and metastatic lung cancer. This approval covers a wider range of bladder cancer patients than currently allowed in the U.S. and follows founder Patrick …

Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis

Immunome Inc (IMNM) currently has a valuation score of 8.36, placing it 136th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -9.69, which is significantly below its recent high and slightly above its recent low. Key …

Why (IMVT) Price Action Is Critical for Tactical Trading

This article provides a critical analysis of Immunovant Inc. (IMVT) stock's price action for tactical trading, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …

(IMNM) Volatility Zones as Tactical Triggers

This article analyzes Immunome Inc. (NASDAQ: IMNM), identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report also notes a …

Trading the Move, Not the Narrative: (IMCR) Edition

This article analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different …

ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC

ImmunityBio (IBRX) has been granted marketing authorization in the UAE for its cancer drug ANKTIVA for two indications: BCG-unresponsive NMIBC and checkpoint-refractory metastatic NSCLC. This expands ANKTIVA's approvals to 34 countries, with the NMIBC approval being the first worldwide to cover CIS with/without papillary …

Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day

Zimmer Biomet Holdings Inc. (ZBH) saw its stock decline by 2.25% to $94.96, ending a five-day winning streak. This occurred despite a generally favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both posting gains. The …

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

ImmunityBio's ANKTIVA has received its broadest approval yet in the UAE for non-muscle invasive bladder cancer (NMIBC), covering the entire disease spectrum, and also for metastatic non-small cell lung cancer (NSCLC). This approval marks the fifth jurisdiction to greenlight ANKTIVA, expanding its global reach …

Cathie Wood's Ark Invest Sells Bitmine While Adding to Coinbase and Circle Holdings

Cathie Wood's Ark Invest sold about $4.4 million worth of crypto-related stocks on Wednesday, trimming positions in Ethereum treasury company Bitmine Immersion Technologies, Robinhood, Block, and Bullish after the companies' shares fell. The firm's largest sale was 120,665 shares of Bitmine, valued at about …

Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immix Biopharma Inc (IMMX), detailing its support, resistance levels, and the readings of various technical indicators and moving averages. It presents a summary of "Buy," "Sell," and "Neutral" signals for different indicators and moving averages, offering insights …

ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments

ImmunityBio (NASDAQ:IBRX) shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two cancer indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's international reach to 34 countries and is a significant milestone in …

Immunocore to Detail Its Business and Portfolio on Aug. 6

Immunocore (NASDAQ: IMCR) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, for the period ending June 30, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT to discuss the results and provide updates on its …

Immutep's IMP761 Shows Immune Activity in First-in-Human Trial

Immutep (NASDAQ: IMMP) released its Q4 FY26 activities report, detailing new clinical, intellectual property, and financial developments. Key highlights include positive pooled analysis from efti trials showing a 7.7-month median overall survival benefit for biological responders and promising first-in-human data for IMP761, which met …

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Immunocore Holdings plc (Nasdaq: IMCR) announced it will report its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026. Following the announcement, the company will host a live teleconference and webcast at 8:00 AM ET to discuss these …